Kyle Mitchell

P1.079. Real-World Adoption of Adjuvant Immunotherapy Following Trimodality Therapy for Esophageal Cancer: A National Cancer Database Analysis

Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Following CheckMate 577 (CM577, 2021), adjuvant nivolumab was approved for patients with esophageal cancer (EC) and residual disease following trimodality therapy. As perioperative paradigms continue...